Author Archives: Marta Figueiredo PhD

Standard MG Care Less Effective for Women, Danish Study Suggests

Women with myasthenia gravis (MG) given standard treatment improve significantly less in both objective and patient-reported outcome measures than do men, a study in Denmark with nearly five years of follow-up data reported. Notably, this sex difference was independent of age, disease duration, simultaneous health conditions (comorbidities), and prior…

#AANAM – Study Examines Seronegative Characteristics

Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read stories from the conference. Myasthenia gravis (MG) patients who test negative for the presence of the most common MG self-reactive antibodies (autoantibodies) more…

Big Early Effects in Immunosuppressive Therapy Predict Better Outcomes

Greater reductions in the levels of antibodies against the acetylcholine receptor (AChR) within the first three months after immunosuppressive treatment in people with myasthenia gravis (MG) are associated with better one-year post-therapy outcomes, a study shows. These findings suggest that measuring anti-AChR antibodies shortly after the start of such therapy…

Disease Crisis Linked to Distinct Pro-inflammatory Immune Changes

Myasthenia gravis (MG) crisis, the disease’s most severe state, is associated with pronounced pro-inflammatory cellular and molecular changes, a recent study shows. Notably, several pro-inflammatory immune cells and molecules were found to be associated with symptom severity, adding to previous data showing a link between certain pro-inflammatory cells…

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.